Home Cart Sign in  
Chemical Structure| 890190-22-4 Chemical Structure| 890190-22-4

Structure of WDR5-0103
CAS No.: 890190-22-4

Chemical Structure| 890190-22-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

WDR5-0103 is a selective antagonist of WD repeat-containing protein 5 (WDR5) with Kd of 450 nM.

Synonyms: WD-Repeat Protein 5-0103

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of WDR5-0103

CAS No. :890190-22-4
Formula : C21H25N3O4
M.W : 383.44
SMILES Code : O=C(OC)C1=CC=C(N2CCN(C)CC2)C(NC(C3=CC=CC(OC)=C3)=O)=C1
Synonyms :
WD-Repeat Protein 5-0103
MDL No. :MFCD07086826
InChI Key :ZPLBXOVTSNRBFB-UHFFFAOYSA-N
Pubchem ID :6457069

Safety of WDR5-0103

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H361-H372-H410
Precautionary Statements:P201-P264-P280-P301+P330+P331-P312
Class:9
UN#:3077
Packing Group:

Related Pathways of WDR5-0103

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
T47D 10 μg/ml 48 hours WDR5-0103 significantly reduced CSCs (Oct4ahi) and increased late BC progenitors (Oct4aneg), indicating that the inhibitor induced CSC differentiation. PMC10863086
MDA-MB-231 10 μg/ml 48 hours Evaluate the toxicity of HTCG@TA on MDA-MB-231 cells, results showed only 32% cell survival PMC10863086
CAFs (Cancer-Associated Fibroblasts) 10 µmol/L 72 hours To evaluate the effect of WDR5-0103 on the overall H3K4me3 level in CAFs, results showed WDR5-0103 significantly reduced H3K4me3 levels PMC11833673

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice Breast cancer dormancy model Intraperitoneal injection 2 mg/kg Administered on days 3 and 5, duration of 7 days KMT2B and KMT2D KD BCCs showed significantly reduced metastasis to the brain, indicating that targeting H3K4 can reduce brain metastasis. PMC10863086
Mice Alzheimer's disease model Intraperitoneal injection 2.5 mg/kg Once daily for 3 days WDR5-0103 significantly reduced H3K4me3 levels in P301S Tau mice, ameliorated cognitive deficits and synaptic function PMC7725456

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.61mL

0.52mL

0.26mL

13.04mL

2.61mL

1.30mL

26.08mL

5.22mL

2.61mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories